Search

Your search keyword '"Elzi, L"' showing total 475 results

Search Constraints

Start Over You searched for: Author "Elzi, L" Remove constraint Author: "Elzi, L"
475 results on '"Elzi, L"'

Search Results

51. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy

52. Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand

55. Height and timing of growth spurt during puberty in young people living with vertically acquired HIV in Europe and Thailand

57. Evaluation of treatment outcomes for Stenotrophomonas maltophilia bacteraemia

60. Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV‐positive people without viral hepatitis in the Swiss HIV Cohort Study.

61. Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIRaben-1 subtype B and non-subtype B receiving a salvage regimen

62. Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection

63. Liver-related death among HIV/hepatitis C virus-co-infected individuals

64. Morbidität und Mortalität der HIV-Infektion

65. Secular Trend and Risk Factors for Antimicrobial Resistance in Escherichia coli Isolates in Switzerland 1997-2007

66. Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012

67. Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV

68. Factors Associated with the Incidence of Type 2 Diabetes Mellitus in HIV-Infected Participants in the Swiss HIV Cohort Study

69. Ageing with HIV: medication use and risk for potential drug-drug interactions

70. The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals

71. Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals

72. Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide

73. Hepatitis B Virus Infection Is Associated With Impaired Immunological Recovery During Antiretroviral Therapy in the Swiss HIV Cohort Study

74. Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population

75. Anti-apolipoprotein A-1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patients

76. Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study

77. Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study

78. Expansion of interferon-γ-secreting HIV-specific T cells during successful antiretroviral therapy

79. Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study

80. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

81. Infection-related and -unrelated malignancies, HIV and the aging population

82. Tuberculosis-related mortality in people living with HIV in Europe and Latin America: An international cohort study

83. Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIRaben-1 subtype B and non-subtype B receiving a salvage regimen

84. Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors

85. A Simple Visual Analog Scale is a Valuable Tool to Assess Self-Reported Adherence in HIV-Infected Patients on Antiretroviral Treatment in a Resource-Limited Setting

86. Increases in Condomless Sex in the Swiss HIV Cohort Study

87. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study

88. Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients

89. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

90. Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013

91. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

92. Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIRaben-1 subtype B and non-subtype B receiving a salvage regimen

93. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

94. Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study

95. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations

96. Development of a definition for rapid progression (RP) of renal function in HIV-positive persons:the D:A:D study

97. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

98. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

99. Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe

100. The interplay between host genetic variation, viral replication and microbial translocation in untreated HIV-infected individuals

Catalog

Books, media, physical & digital resources